Kymera Therapeutics
KYMR· Manufacturing· Fiscal year ends in December
No proxy on file names the CEO of Kymera Therapeutics.
Executives4
See all- 1Brian Adams, J.D.Chief Legal OfficerFY2025
- 2Noah Goodman, MBAChief Business OfficerFY2025
- 3Jared Gollob, M.D.Chief Medical OfficerFY2025
- 4Bruce Jacobs, CFA, MBAChief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allKymera Therapeutics paid its 5 named executives $23.6M in total in FY2025 (Dec).
| Name | |||
|---|---|---|---|
| Brian Adams, J.D.Chief Legal Officer | Not disclosed | Not disclosed | |
| Noah Goodman, MBAChief Business Officer | Not disclosed | Not disclosed | |
| Jared Gollob, M.D.Chief Medical Officer | |||
| Bruce Jacobs, CFA, MBAChief Financial Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers18
See allThe FY2025 (Dec) proxy of Kymera Therapeutics names 18 peer companies for pay. Among Kymera Therapeutics and these peers, CEO pay was 7th highest of 10 and total shareholder return was 7th highest of 10.
7th highest of 10in Kymera Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
7th highest of 10in Kymera Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board4
See all- Felix J. Baker, Ph.D.Lead independent director · 1 yr on the boardIndependentCompensation—Paid as an executive
- Gorjan HrustanovicDirector · 5 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- Pamela Esposito, Ph.D.Director · 5 yr on the boardIndependentAudit, Nominating and Corporate Governance (Chair)—Paid as an executive
- John Maraganore, Ph.D.Director · 3 yr on the boardIndependentCompensation—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 29, 2026 | FY2025 |
| Annual report | 10-K | Feb 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 29, 2025 | FY2024 |
| Annual report | 10-K | Feb 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 24, 2024 | FY2023 |
| Annual report | 10-K | Feb 22, 2024 | FY2023 |